tbuckley/cabot-search huggingface dataset:
Abstract P6-03-04: TGF-β receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer
Authors: Bojana Jovanovic, J Scott Beeler, Michael W Pickup, Anna Chytil, Agnieszka E Gorska, William J Ashby, Brian D Lehmann, Andries Zijlstra, Jennifer A Pietenpol, Harold L Moses
Journal: Cancer Research (2015)

Abstract Introduction: There is a major need to better understand the molecular basis of triple negative breast cancer (TNBC) in order to develop effective therapeutic strategies. Using gene expression data from 587 TNBC patients we previously identified six subtypes of the disease, among which a Mesenchymal-Stem Like (MSL) subtype. The MSL subtype has significantly higher expression of the transforming growth factor beta (TGF-β) pathway-associated genes relative to other subtypes, including the TGF-β receptor type III (TβRIII). We hypothesize that TβRIII is tumor promoter in mesenchymal-stem like TNBC cells. Methods: Representative MSL cell lines SUM159, MDA-MB-231 and MDA-MB-157 were used to study the roles of TβRIII in the MSL subtype. We stably expressed short hairpin RNAs specific to TβRIII (TβRIII-KD). These cells were then used for xenograft tumor studies in vivo; and migration, invasion, proliferation and three dimensional culture studies in vitro. Furthermore, we utilized human gene expression datasets to examine TβRIII expression patterns across all TNBC subtypes. Results: TβRIII was the most differentially expressed TGF-β signaling gene in the MSL subtype. Silencing TβRIII expression in MSL cell lines significantly decreased cell motility and invasion. In addition, when TβRIII-KD cells were grown in a three dimensional (3D) culture system or nude mice, there was a loss of invasive protrusions and a significant decrease in xenograft tumor growth, respectively. In pursuit of the mechanistic underpinnings for the observed TβRIII-dependent phenotypes, we discovered that integrin-α2 was expressed at higher level in MSL cells after TβRIII-KD. Stable knockdown of integrin-α2 in TβRIII-KD MSL cells rescued the ability of the MSL cells to migrate and invade at the same level as MSL control cells. Conclusions: We have found that TβRIII is required for migration and invasion in vitro and xenograft growth in vivo. We also show that TβRIII-KD elevates expression of integrin-α2, which is required for the reduced migration and invasion, as determined by siRNA knockdown studies of both TβRIII and integrin-α2. Overall, our results indicate a potential mechanism in which TβRIII modulates integrin-α2 expression to effect MSL cell migration, invasion, and tumorigenicity. Citation Format: Bojana Jovanovic, J Scott Beeler, Michael W Pickup, Anna Chytil, Agnieszka E Gorska, William J Ashby, Brian D Lehmann, Andries Zijlstra, Jennifer A Pietenpol, Harold L Moses. TGF-β receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-03-04.
The utility of electromyographic biofeedback in the treatment of conversion paralysis
Authors: D A Fishbain, M Goldberg, T M Khalil, S S Asfour, E Abdel-Moty, B R Meagher, R Santana, R S Rosomoff, H L Rosomoff
Journal: American Journal of Psychiatry (1988)

Conversion paralysis has a poor prognosis when there is evidence of nonresponse to previous treatment, long duration, and secondary atrophy of the "paralyzed" muscles. The authors present four such cases in which conversion paralysis was treated successfully by means of electromyographic (EMG) biofeedback. Each of the four patients also suffered from a chronic pain condition. Results from statistical analyses indicated that the four patients demonstrated significant improvement in the functional capacity of the "paralyzed" muscles as measured by isometric maximum voluntary contraction and EMG activity. The improvements occurred without explicit psychotherapy and suggest that behavioral modification techniques alone may be helpful in such cases.
Erdheim-Chester disease in Brazil
Authors: C D L. Marques
Journal: Annals of the Rheumatic Diseases (2003)

reuil et al reported on a patient with Erdheim-Chester disease. 1 We would like to add our experience in a patient who had a good response to steroids.A 46 year old housewife, born in Maceio (Brazil), complained of pain in her legs for a period of eight months, which interfered with her sleep; there were no constitutional symptoms, such as weight loss, asthenia, or fever.On physical examination, there was no systemic involvement or bone inflammation, except for tenderness on palpation of both tibiae.An x ray examination showed bilateral and symmetrical cortical osteosclerosis of the diaphysial regions of the tibiae, which was better illustrated with magnetic resonance imaging (MRI) which showed a low signal on T 1 and a high signal on T 2 of the medullar canal (fig 1).Bone scintigraphy showed intense hypercapitation at the upper and medial regions of the right tibia and the medial region of the left tibia (fig 2).Other MR images (brain, thorax, and abdomen) were normal.A bone biopsy showed only osteosclerosis, which has been described in this disease. 2 She was treated with steroids for six months (prednisone 20 mg/day) and responded well, being asymptomatic and receiv-ing no treatment since December 2000.As bone pain is the first symptom of this xanthogranulomatosis, rheumatologists should be able to recognise the disease in an early phase when treatment gives a better outcome.. . . .
615. Feasibility of hTERT-Targeting Trans-Splicing Ribozyme in Tumor-Targeted Gene Therapy
Authors: Seung-Hee Hong, Yoon-Jong Lee, Haeng-Im Jung, Byung-Su Kwon, Seong-Wook Lee, Jin-Sook Jeong, Chang-Min Kim, In-Hoo Kim
Journal: Molecular Therapy (2004)

Cancer gene therapy without toxicity is hampered by lack of efficient tumor-directed therapeutic gene expression system. In the present study, we describe a new tumor-targeted gene therapy tool that is based upon trans-splicing ribozymes. Trans-splicing ribozymes are RNA-based catalysts capable of performing both cleavage and ligation reaction in target RNA. Thus a chimeric mRNA can be produced and new gene activities triggered in cells dependent on the presence of the target RNA. We chose hTERT-targeting trans-splicing ribozyme for efficient tumor-directed expression of therapeutic gene by transcriptional targeting and RNA replacement because human telomerase reverse transcriptase (hTERT) is expressed at high levels in 90% of malignant tumors and tumor cell lines but is absent in normal postmitotic tissues. After developing a group I intron-based ribozyme targeting hTERT with high fidelity and specificity, we constructed novel adenoviral vectors containing hTERT-targeting trans-splicing ribozymes with downstream lacZ gene (Ad-ribolacZ) or herpes simplex virus thymidine kinase gene (Ad-ribotk). This hTERT-targeting trans-splicing ribozyme could simultaneously reduce hTERT expression and trigger expression of a new gene, such as lacZ or HSVtk, in cells expressing hTERT. To determine whether new gene activity could be selectively induced in hTERT expressing cells by trans-splicing ribozyme, we transfected Ad-ribolacZ into hTERT-positive and -negative cell lines. Then lacZ expression was analyzed by X-gal staining and β-galactosidase enzyme activity assays. We observed 4 to 9-fold increase of lacZ expression in hTERT-positive cells but not in h-TERT-negative ones. In contrast, induction of lacZ expression by adenovirus harboring lacZ gene driven by CMV promoter (Ad-CMVlacZ) could be observed in both hTERT-negative and-positive cells. Those results suggest that selective induction of transgene activity in hTERT-dependent manner by Ad-ribolacZ was mediated by correct targeting of hTERT with trans-splicing ribozyme in hTERT-positive cells. Given the observation that the trans-splicing ribozyme induced transgene expression selectively in target RNA-expressing cells, we determined whether the ribozyme would trigger selective cytotoxicity in hTERT-expressing cells. After transfecting Ad-ribotk into hTERT-positive and -negative cell lines, selective cytotoxicity was monitored by MTT assays. Ad-CMVtk was used as control. We could observe that Ad-ribotk revealed more than 50% reduction in survival rate of hTERT-positive cells, while not in hTERT-negative ones. In control, reductions of cell survival were observed regardless of hTERT expression. Those observation of highly selective cytotoxicity rendered by Ad-ribotk suggest that hTERT-targeting trans-splicing ribozyme may be one of powerful tools in tumor-targeted gene therapy.
The residual megakaryocyte and platelet production in c-Mpl–deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor
Authors: Timothy Gainsford, Harshal Nandurkar, Donald Metcalf, Lorraine Robb, C. Glenn Begley, Warren S. Alexander
Journal: Blood (2000)
Comprehensive Analysis of Mortality Among Patients Undergoing TAVR
Authors: Lars G. Svensson, Eugene H. Blackstone, Jeevanantham Rajeswaran, Nicholas Brozzi, Martin B. Leon, Craig R. Smith, Michael Mack, D. Craig Miller, Jeffrey W. Moses, E. Murat Tuzcu, John G. Webb, Samir Kapadia, Gregory P. Fontana, Raj R. Makkar, David L. Brown, Peter C. Block, Robert A. Guyton, Vinod H. Thourani, Augusto D. Pichard, Joseph E. Bavaria, Howard C. Herrmann, Mathew R. Williams, Vasilis Babaliaros, Philippe Généreux, Jodi J. Akin
Journal: Journal of the American College of Cardiology (2014)
Book: Medicine's 10 Greatest Discoveries
Authors: C. Lawrence
Journal: BMJ (1999)

Meyer Friedman, Gerald W Friedland Yale University Press, £19.95, pp 320 ISBN 0 300 07598 7 Rating: ![Graphic][1]</img> Meyer Friedman is described on the jacket of this book (and presumably describes himself) as “the discoverer of Type A behavior and its relation to heart disease.” This description seems to sum up the philosophy underlying the volume: that is, individuals make discoveries on a once and for all basis. But, that there is a type A behaviour is not universally agreed, a fact suggesting that, besides individual creativity, discoveries are things made over time, needing the assent of a relevant … [1]: /embed/inline-graphic-1.gif
Abstract 14967: The Adverse Economic Impact of Inpatient Hospitalization for Evaluation of Patients with Unexplained Syncope
Authors: Suneet Mittal, Carol Grebowiec, Jonathan S Steinberg
Journal: Circulation (2012)

Background: Syncope often prompts an ER visit and subsequent hospitalization. Hospital reimbursement for Medicare pts with syncope is based on a DRG; increasingly, payment is being denied because p...
Exclusion of expansion of 50 CAG/CTG trinucleotide repeats in bipolar disorder
Authors: C Guy, T Bowen, J K Daniels, G Speight, P McKeon, L Mynett-Johnson, E Claffey, P McGuffin, M J Owen, N Craddock, M C O'Donovan
Journal: American Journal of Psychiatry (1997)

The purpose of this study was to identify the specific expanded CAG/CTG trinucleotide repeat associated with bipolar disorder.The study employed an efficient multistage approach for using a genomic CAG/CTG screening set.The authors found no evidence of expanded repeats at 43 polymorphic autosomal loci and seven X chromosomal loci. Secondary screening was pursued at the only locus that contained a large allele (37 repeats) in the primary screening. No association was found between allele size and diagnostic status.It is highly unlikely that expansions in repeat size at any of the 50 candidate trinucleotide repeat loci examined are responsible for the association between expanded CAG/ CTG repeats and bipolar disorder. However, although the authors prioritized the repeats that were a priori most likely to be involved, the study does not reject the more general hypothesis that expanded CAG/CTG repeats are implicated in the pathogenesis of bipolar disorder.
HYPERTENSION CAUSED BY UNILATERAL KIDNEY DISEASE
Authors: J. Shirley Sweeney, John M. Pace
Journal: Annals of Internal Medicine (1943)

Case Reports1 December 1943HYPERTENSION CAUSED BY UNILATERAL KIDNEY DISEASEJ. SHIRLEY SWEENEY, M.D., SC.D., F.A.C.P., JOHN M. PACE, M.D.J. SHIRLEY SWEENEY, M.D., SC.D., F.A.C.P., JOHN M. PACE, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-19-6-1013 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptNumerous reports of unilateral renal disease associated with hypertension have appeared in the literature since the epochal researches of Goldblatt. The purpose of this report is to add to the literature one more case of what seems to be a perfectly typical atrophic kidney which was associated with marked hypertension.CASE REPORTThe patient, Miss M. J. M., aged 21, consulted one of us on May 3, 1941. She was referred by her family physician because of high blood pressure. Her family history was entirely negative. Her menstrual history likewise was perfectly normal. Her only illness during childhood was measles,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Dallas, Texas*Received for publication May 1, 1942. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHypertonieHypertonieClinical Characteristics of Hypertension Associated with Unilateral Renal DiseaseHypertension and urologic diseaseHypertension in Unilateral Renal Disease 1 December 1943Volume 19, Issue 6Page: 1013-1017KeywordsBirthBlood pressureHypertensionKidneysMeaslesPregnancyPrimary hypertensionRenal diseases ePublished: 1 December 2008 Issue Published: 1 December 1943 PDF downloadLoading ...
Fluvoxamine alone in the treatment of delusional depression
Authors: Flavia Gatti, Laura Bellini, Mariangela Gasperini, Jorge Perez, Raffaella Zanardi, Enrico Smeraldi
Journal: American Journal of Psychiatry (1996)

The aim of this study was to evaluate the efficacy of fluvoxamine in the treatment of delusional depression.Fifty-nine inpatients who met the DSM-III-R criteria for major depression with psychotic features were treated with fluvoxamine for 6 weeks. Patients were assessed at baseline and weekly thereafter with the Hamilton Depression Rating Scale and the Dimensions of Delusional Experience rating scale.Of the 57 subjects completed the trial, 84.2% (N=48) recovered. The index episodes of the patients who did not respond to fluvoxamine were of significantly longer duration than those of the responders.Fluvoxamine has a response rate similar to that of the currently most efficacious treatments for delusional depression, including antidepressants plus antipsychotics and ECT.
Is Seminal Vesicle Ablation Mandatory for All Patients Undergoing Radical Prostatectomy?
Authors: Alexandre R Zlotta, Thierry Roumeguère, Vincent Ravery, Paul Hoffmann, Francesco Montorsi, Levent Türkeri, Michael Dobrovrits, Vincenzo Scattoni, Samuel Ekane, Renaud Bollens, Marc Vanden Bossche, Bob Djavan, Laurent Boccon-Gibod, Claude C Schulman
Journal: European Urology (2004)
ALLERGIC CORYZA AT MENSTRUATION FROM OVARIAN HORMONE
Authors: Frank A. Riebel
Journal: Annals of Internal Medicine (1935)

Case Reports1 July 1935ALLERGIC CORYZA AT MENSTRUATION FROM OVARIAN HORMONEFRANK A. RIEBEL, M.D.FRANK A. RIEBEL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-9-1-91 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe symptoms which may be associated with menstruation are numerous and varied. The majority of them are plainly the result of the cyclic functional and structural changes in the genital tract; but occasionally the history suggests an allergic basis for the phenomena. Such a case is described here.CASE REPORTE. S., married, a white female aged 29, complained of frequent attacks of coryza; these began regularly the day before or the first day of her menstrual period. The initial symptoms were malaise and frontal headache, and these were followed by sneezing, nasal obstruction, chills, fever of about 101°, and... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Columbus, Ohio*Received for publication May 21, 1935. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySex hormone allergy: clinical aspects, causes and therapeutic strategies – Update and secondary publicationHormone AllergyAutoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature reviewEtiologia da tensão pré-menstrual: revisão da literaturaSystemic changes during the menstrual cycleULCERATIVE STOMATITIS CAUSED BY ENDOGENOUS PROGESTERONE*HERBERT BERGER, M.D., F.A.C.P.Endocrine Allergy. Clinical Reactions of Allergy to Endogenous Hormones and their Treatment*Menstruation and its disorders 1 July 1935Volume 9, Issue 1Page: 91-92KeywordsFeversGenital anatomyHeadachesHormonesSneezing ePublished: 1 December 2008 Issue Published: 1 July 1935 PDF downloadLoading ...
Montezuma's Revenge
Authors: Judith Skillman
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The regulation of antidiuretic hormone release in man
Authors: William E. Segar, Ward W. Moore
Journal: Journal of Clinical Investigation (1968)

It has been postulated that alterations in the intravascular distribution of blood affect antidiuretic hormone (ADH) secretion in man. The studies reported here were designed to alter blood distribution by thermal and by positional change to test this thesis.HUMAN BLOOD ADH LEVELS HAVE BEEN SHOWN TO VARY WITH POSITION: a mean value of 0.4 +/- 0.6 (SD) muU/ml was obtained while the subject was supine, a value of 1.4 +/- 0.7 muU/ml while sitting, and 3.1 +/- 1.5 muU/ml while standing. In 79 control subjects, sitting comfortably for 30 min in a normal environment, a blood ADH level of 1.65 +/- 0.63 muU/ml was found. It is suggested that subjects assume this position during experiments in which blood is drawn for measurement of ADH levels.In eight seated subjects the ADH level rose from 1.6 +/- 0.4 to 5.2 +/- 0.8 muU/ml after a 2 hr exposure at 50 degrees C and fell to 1.0 +/- 0.26 muU/ml within 15 min at 26 degrees C.Six subjects with a mean ADH level of 2.2 +/- 0.58 muU/ml sat quietly in the cold (13 degrees C) for 1 hr, and the ADH level fell to 1.2 +/- 0.36 muU/ml. After 15 min at 26 degrees C, the level rose to 3.1 +/- 0.78 muU/ml. The serum sodium and osmolal concentrations remained constant during all studies.Water, sodium, and total solute excretion decreased during exposure to the heat, whereas the urine to plasma (U/P) osmolal ratio increased. During cold exposure, water, sodium, and total solute excretion increased, and there was a decrease in the U/P osmolal ratio.These data are interpreted as indicating that changes in activity of intrathoracic stretch receptors, in response to redistribution of blood, alter ADH secretion independently of changes in serum osmolality. The rapidity of change of blood ADH concentration indicates a great sensitivity and a prime functional role for the "volume receptors" in the regulation of ADH secretion.
>18F-labeled BPA positron emmision tomography (PET) based Boron Neutron Capture Therapy on malignant glioma patients in Japan
Authors: Shinji Kawabata, Shin-Ichi Miyatake, Minoru Miyashita, Atsushi Doi, Kyouko Iida, Toshihiko Kuroiwa, Yoshio Imahori, Koji Ono
Journal: Clinical Cancer Research (2006)

B79   Boron neutron capture therapy (BNCT) is based upon the nuclear reaction that occur when non-radioactive boron-10 ( 10 B) is irradiated with low energy neutrons to produce high energy a particles ( 10 B[n,alpha]  7 Li). In order for BNCT to be successful, a sufficient amount of  10 B and neutrons must be delivered to the tumor.We have treated a group of 40 patients with high grade gliomas using a combination of surgery followed by BNCT. This was carried out at the Kyoto University Research Reactor Institute (KURRI) using an epithermal neutron beam for enhanced tissue penetration together with use of two different boron drugs, sodium borocaptate (BSH) and boronophenylalanine (BPA), both of which have been used clinically. Forty patients were treated between 2002 and 2006 at Osaka Medical College. 18 F-labeled BPA positron emmision tomography (BPA-PET) has been applied for the estimation of the boron compound accumulation prior to BNCT [Imahori Y, Clin Cancer Res,1998]. We use the dose-planning work station SERA to calculate irradiation dose for tumor from BPA-PET data and patients blood sampling data from every 2 hours after BSH administration. Using BPA-PET, the residual tumor:normal brain (T/N) ratio varied from 2.1 to 7.1 (mean 4.0). Tumor boron concentrations of BSH and BPA varied from 17 to 32 μg/g, and from 34 to 98 μg/g, respectively. As a result of these estimation, we decide the neutron irradiation time and the total radiation dose delivered to normal brain was less than 13 Gy-Eq, and the estimated maximum dose delivered to residual tumor was from 44.6 to 64.8 Gy-Eq.Clinical response was assessed by MRI imaging, and this initially revealed a 17 to 71% (mean 51.5%) reduction in the residual tumor enhancing volume and this subsequently increased to 30 to 88 % (mean 61.7%). Reduction in tumor volume and a decrease in edema in brain around the tumor were recognized in many cases.Main causes of die were CSF dissemination and local tumor recurrence from the lesion with low T/N ratio. This could be attributed to an insufficient  10 B(n,alpha)  7 Li capture reaction in more deep seated regions of the tumor. Nevertheless, there was clear evidence of a favorable response, as evidenced radiographically, and further modifications will be made in the treatment protocol to further improve the clinical results.Analyze the drug accumulation prior to individual treatment was useful for think about therapy effect and for reduce side effect. BPA is accumulated depends on the tumor metabolism of amino acids and it is variable in each cases. So, BPA-PET was very useful for our modified BNCT and this should become important concept for any kinds of cancer targeting therapy in near future.